Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imunon, Inc. is conducting a Phase 3 clinical trial titled A ...

DelveInsight's,“ Fallopian Tube Cancer Pipeline Insight 2025 ” report provides comprehensive insights about 70+ Fallopian ...

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.

Q2 2025 Management View Stacy R. Lindborg, President and CEO, reported unprecedented improvement in overall survival for ...

Imunon, Inc. ( NASDAQ: IMNN) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Douglas V. Faller - Chief Medical Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Kimberly ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 million in June, management is pushing ahead with plans to find partners ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

Analysts expect Imunon to report an earnings per share (EPS) of $-3.09. The market awaits Imunon's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), ...

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate, IMNN-001.

LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the ...